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Enterohemolysin produced by Escherichia coli associated with infant
diarrhea showed characteristics similar to those of thiol-activated
hemolysins produced by Gram-positive bacteria, including inactiva-
tion by cholesterol, lytic activity towards eukaryotic cells and
thermoinstability. However, enterohemolysin activity was not inacti-
vated by oxidation or by SH group-blocking agents (1 mM HgCl2,
1 mM iodoacetic acid) and the hemolysin (100 µg/ml) was not lethal
to mice, in contrast to the lethality of the thiol-activated hemolysin
family to animals. Earlier reports showed that intravenous injection of
partially purified streptolysin O preparations (0.2 µg) was rapidly
lethal to mice. These results suggest that E. coli enterohemolysin is not
a thiol-activated hemolysin, despite its ability to bind cholesterol,
probably due to the absence of free thiol-group(s) that characterize the
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Escherichia coli produces various types
of hemolysins (1), the most extensively stud-
ied is α-hemolysin (2). A novel hemolysin
produced by E. coli strains belonging to se-
rogroups O26 and O111 and known as
enterohemolysin (EHly) was first detected
by Beutin et al. (3). In contrast to α-hemoly-
sin, which is more frequent in E. coli strains
causing extraintestinal infections in humans
(2) and is associated with enteric disease
(3,4), this EHly is not expressed by cultures
grown without shaking, is not secreted into
the culture medium by the bacteria, and can
be detected only on blood-agar plates con-
taining washed erythrocytes (3,4). E. coli
enterohemolysin is structurally and geno-
typically unrelated to the α-hemolysin of this
species, and is encoded by temperate phages.
The gene structure of this hemolysin is still
unknown. A 60-kDa outer membrane pro-
tein, present only in EHly-positive bacteria
(5), may be the EHly itself, but no further
information on the purification of this pro-
tein is available. In the present paper, we
describe the purification of EHly and show
that it shares several properties with thiol-
activated hemolysins having the following
general characteristics, in addition to being
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inactivated by cholesterol: inactivation by
oxidation and reactivation with reducing
agents, lethality to mice, and lytic activity
towards eukaryotic cells through the forma-
tion of pores in the cell membrane (6).
E. coli strain C3888 (O26: H-; Stx-), kindly
provided by Lothar Beutin (Robert Koch
Institute, BGA, Berlin, Germany), was used
for EHly purification. The strain was main-
tained as frozen stock cultures at -70ºC in
20% glycerol plus trypticase soy broth (TSB;
Difco, Detroit, MI, USA). E. coli strain C3888
was initially inoculated in 5 ml of TSB,
followed by incubation for 18 h at 37ºC. One
milliliter of the seed culture was then trans-
ferred to Erlenmeyer flasks containing 500
ml of fresh TSB with 12 µg/ml ethylenedi-
amine hydroxyphenylacetic acid (EDDA)
and incubated for 22 h at 37ºC, with constant
shaking at 150 rpm (New Brunswick Scien-
tific, Edison, NJ, USA). Cultures were cen-
trifuged at 10,000 g for 15 min at 4ºC and the
supernatant was discarded. The cell pellet
was then suspended in 100 ml of 10 mM
Tris-HCl buffer, pH 7.6, and disrupted by
ultrasonication (10 cycles of 10 s each with a
50% energy pulse) in a cell disrupter (Vibra
Cell, Sonics, Newtown, CT, USA). This was
followed by centrifugation for 20 min at
12,000 g and the resulting supernatant was
used as a source of crude EHly (3).
The supernatant was precipitated with
ammonium sulfate to 45% saturation at 4ºC.
After centrifugation, the supernatant was ad-
justed to 60% saturation at 4ºC. This second
precipitate was collected by centrifugation
as described above and dissolved in 20 ml of
10 mM Tris-HCl, pH 7.6. The solution was
dialyzed against the same buffer at 4ºC for
18 h.
The resulting material (420 mg) was ap-
plied to a DEAE Sepharose fast flow column
equilibrated with 10 mM Tris-HCl, pH 7.6 (4
cm x 34 cm; Pharmacia LKB Biotechnology,
Buckinghamshire, England). Fractions (10
ml/tube) revealing the hemolytic activity were
collected and concentrated to 2.5 ml by mem-
brane ultrafiltration (PM-50 Diaflo, Amicon
Corp., Lexington, MA, USA). The concen-
trated hemolysin (2.4 mg) was applied to a
Superdex 200 column (1.6 cm x 90 cm;
Pharmacia LKB) equilibrated with 10 mM
Tris-HCl, pH 7.6, containing 0.15 M NaCl.
The material obtained by chromatography
represented partially purified EHly and was
used in the biological tests. As the final
purification step, the material (0.23 mg) from
the preceding step was applied to an HR 5/5
Mono-Q anion-exchange column (Pharma-
cia LKB) for fast protein liquid chromatog-
raphy. The fractions with hemolytic activity
were stored at -20ºC.
Polyacrylamide gel electrophoresis in the
presence of 0.1% sodium dodecyl sulfate
(SDS-PAGE) was carried out using a slab
gel system (7) in a BioRad Mini-Protean II
apparatus (BioRad Laboratories, Hercules,
CA, USA) with phosphorylase b, albumin,
ovalbumin, carbonic anhydrase, trypsin in-
hibitor, and α-lactalbumin as the standards
and protein concentrations were determined
by the method of Bradford using a BioRad
Protein assay kit (BioRad Laboratories) with
bovine serum albumin as the standard.
The hemolytic activity of partially puri-
fied EHly was assayed by incubating 100 µl
of pure sample or dilutions (1:2, v/v) with an
equal volume of 2% sheep erythrocytes
washed three times with PBS, pH 7.2, for 1 h
at 37ºC in round-bottom 96-well microtiter
plates (8). One hemolytic unit was defined
as the amount of hemolysin causing 50%
hemolysis of 100 µl of a 2% suspension of
sheep erythrocytes after 60 min at 37ºC.
The influence of cholesterol on hemolyt-
ic activity was tested as described by Geoffroy
et al. (9). An alcoholic solution of choles-
terol, 10 mg/ml, was diluted serially (two-
fold dilutions) on 96-well microtiter plates
to a concentration of 50 µg/ml, after which
the cholesterol was incubated for 60 min at
37ºC with aliquots of purified EHly fol-
lowed by 18 h at 4ºC. The hemolytic activity
was detected by incubating the above mix-
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ture with a 1% suspension of erythrocytes
for 60 min at 37ºC. Purified EHly was also
incubated for 20 min at 37ºC with some SH
group-blocking agents (1 mM HgCl2, 1 mM
iodoacetic acid), with H2O2 (30, 20 and 10 v)
and with some reducing agents (1 mM di-
thiothreitol, 2 mM cysteine and 1 mM gluta-
thione) (10). The residual hemolytic activity
was determined by incubating the mixtures
with sheep erythrocytes at 37ºC for 60 min.
The susceptibility of Vero, HeLa, CHO,
3T3, HEp-2 and Caco-2 cells to the cyto-
toxic or cytostatic activity of purified EHly
was assayed as reported by Konowalchuk et
al. (11). All cells were grown in Eagle’s
minimal essential medium (EMEM; Sero-
med, Biochrom KG, Berlin, Germany) with
10% fetal bovine serum (Sigma, St. Louis,
MO, USA), as described by MacLeod and
Gyles (12). Monolayers were established on
36-well plastic plates, using 0.1 ml of cell
culture (2 x 105 cells/ml). For Caco-2 cells,
24-well plates containing 1 ml of cell culture
were used. The plates were incubated at
37ºC for 7 days in a 5% CO2 atmosphere.
Purified EHly (100 µg/ml) was serially di-
luted in two-fold dilutions with EMEM be-
fore adding to the wells. The plates were
incubated at 37ºC in a 5% CO2 atmosphere
and observed at 5-h intervals for 72 h.
Mouse lethality was assayed in 6-week-
old male Swiss and BALB/c mice (N = 5)
inoculated intravenously and intraperitone-
ally with 100 µl of purified EHly (100 µg/
ml). Five mice were also used in the control
group. Deaths were recorded over a 7-day
period. EHly was purified about 100-fold
with a recovery of 0.06% and a molecular
mass estimated at 60 kDa by SDS-PAGE
(data not shown). The storage of purified
material at -20ºC overnight also led to com-
plete loss of hemolytic activity. The hemo-
lytic activity of partially purified EHly was
stable for as long as two months with freez-
ing and was inactivated after heating at 60º
and 100ºC for 5 min. There was no inactiva-
tion by SH group-blocking agents and H2O2
or alteration by reducing agents, but choles-
terol concentrations of ≥2.5 mg/ml fully in-
hibited total hemolysis, whereas concentra-
tions of 1.25-2.3 mg/ml produced only par-
tial inhibition (Table 1). Partially purified
EHly (100 µg/ml) obtained by Superdex 200
chromatography was cytotoxic to HEp-2,
HeLa, Caco-2, Vero, 3T3 and CHO cells,
and produced cell rounding and detachment
of the cell layer after 24 h. The effect ob-
Table 1. Inhibition of the hemolytic activity of
enterohemolysin by cholesterol.












Figure 1. Effect of Escherichia coli enterohemolysin (EHly) on Caco-2 and CHO cells. A,
Control Caco-2 cells; B, Caco-2 cells exposed to EHly; C, control CHO cells; D, CHO cells
exposed to EHly. The bar corresponds to 20 µm.
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served in Caco-2 and CHO cells is shown in
Figure 1. EHly was not lethal to mice when
injected intraperitoneally or intravenously.
In the present study, we purified the EHly
produced by E. coli strain C3888. Attempts
to increase the production of EHly by vary-
ing the culture medium, incubation time and
iron chelant levels were ineffective. Since a
slight increase in toxin production was ob-
tained using TSB containing EDDA, a medi-
um was used to provide material for purifi-
cation. The specific activity and the relative
activity increased approximately 100 times.
EHly lost considerable activity within a few
hours during the final steps of purification
and different solutions and protease inhibi-
tors in Tris-HCl buffer containing 0.1 M
CaCl2 and 0.3 M Na2SO4 were used to mini-
mize this effect (13,14). Although some sta-
bility was obtained, the hemolytic activity of
purified EHly could still not be maintained.
This difficulty justifies the use of the Super-
dex fractions (partially purified EHly) in the
biological tests. The purified material yielded
a single protein band of approximately 60
kDa by SDS-PAGE (data not shown), a re-
sult consistent with that obtained by Beutin
et al. (5), who described a membrane protein
of 60 kDa associated with EHly. Stroeher et
al. (15) found outer membrane proteins of
33-35 and 65 kDa associated with EHly for
both the EHly+ and EHly- strains, with the
65-kDa protein possibly being an aggregate
or dimer of the 33- to 35-kDa protein. These
results suggest that EHly could be a member
of the thiol-activated hemolysin family, a
prominent group of bacterial toxins of which
streptolysin O is the prototype.
Concentrations of cholesterol higher than
2.5 mg/ml completely inhibited the hemolyt-
ic activity of EHly, while concentrations of
1.25-2.3 mg/ml only partially inhibited this
activity (Table 1). These results suggest that
the factor responsible for the inhibition of
enterohemolytic activity in agar blood-con-
taining non-washed erythrocytes may be cho-
lesterol, which is known to inactive thiol-
activated hemolysin. However, these hemo-
lysins require small amounts of free choles-
terol to inhibit their lytic activity and EHly
requires a concentration of cholesterol 100
times higher to inhibit hemolytic activity in
vitro. These results were similar to those
described by Miyake et al. (16) for inhibition
of the hemolytic activity of Vibrio metschni-
kovii hemolysin and suggest that the two
proteins were not thiol-activated hemolysins.
The foregoing conclusion was supported
by the observation that the lytic activity of
EHly was not inactivated by H2O2 and SH
group-blocking agents or enhanced by re-
ducing agents. The results obtained in the
assays with SH group reagents (thiols) and
reducing agents differed in some features
from the thiol-activated hemolysin family in
which the lytic activity is enhanced by re-
ducing agents but suppressed by oxidation
(17). Thiol-activated hemolysin activity is
inhibited by sulfhydryl-blocking agents and
oxidation because of the existence of free
thiol group(s) (reduced form), which are
characteristic of the active form essential for
the lytic activity of thiol-activated hemoly-
sin. These toxins lose their activity through
the oxidation of thiol groups to disulfide
bonds (6,17). Our results suggest that EHly
has no free thiol group(s) to form the active
site of the molecule, as in Vibrio vulnificus
hemolysin (10).
EHly was cytotoxic to HEp-2, HeLa,
Vero, 3T3, Caco-2 and CHO cells, with
morphological changes including cell round-
ing and detachment of the cell layer, as
described for verotoxin by Konowalchuk et
al. (11). These results differ from those re-
ported by Beutin et al. (3,4), who found no
cytotoxic action of EHly on Vero, HeLa and
HEp-2 cells. Beutin (1) reported that EHly
affected human cultured cells, although the
cell type was not specified. EHly was not
lethal to mice, in contrast to the lethality of
the thiol-activated hemolysin family to ani-
mals (17). The concentration of EHly used
(100 µg/ml) was not lethal to mice, whereas
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intravenous injection of partially purified
streptolysin O preparations killed mice, rats,
rabbits, guinea pigs and cats (18). The aver-
age LD50 for streptolysin O given iv is 0.2, 6
and 2 µg in the mouse, guinea pig and rabbit,
respectively.
Since the first report of EHly in E. coli
strains isolated from children with diarrhea
(3), EHly has been investigated intensively
in enterohemorrhagic E. coli strains that pro-
duce verotoxin and have caused outbreaks
of diarrhea, especially in Germany and the
United States (19,20). The biochemical and
structural aspects of EHly have not yet been
investigated as thoroughly as those of E. coli
α-hemolysin. Further studies with EHly are
necessary in order to establish the impor-
tance of this toxin as a virulence factor and
its possible relation to other proteins pro-
duced by E. coli.
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